Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

5749 - Safety of high doses of somatostatin analogs in well differentiated NENs in elderly


29 Sep 2019


Poster Display session 2


Tumour Site

Neuroendocrine Neoplasms


Massimiliano Cani


Annals of Oncology (2019) 30 (suppl_5): v194-v197. 10.1093/annonc/mdz245


M. Cani1, L. Incorvaia2, D. Fanale2, I. De Luca2, F. Gelsomino3, T. Ibrahim4, S. Pusceddu5, F. Riccardi6, S. Tafuto7, G. Lamberti8, A. Faggiano9, A. La salvia10, M. Albertelli11, S. Massironi12, M. Rinzivillo13, G. butturini14, V. Bazan2, D. campana15, A. Russo2, G. Badalamenti2

Author affiliations

  • 1 Department Of Surgical, Oncological And Oral Sciences, AOU Policlinico "Paolo Giaccone", 90127 - Palermo/IT
  • 2 Department Of Surgical, Oncological And Oral Sciences, University of Palermo, 90127 - Palermo/IT
  • 3 Oncology, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 4 Medical Oncology Unit, IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRCCS, 47014 - Meldola/IT
  • 5 Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 6 Medical Oncology, AORN Cardarelli, UOC di Oncologia, 80121 - Napoli/IT
  • 7 Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT
  • 8 Department Of Medical Oncology, AOU Policlinico S. Orsola-Malpighi, 40138 - Bologna/IT
  • 9 Dipartimento Di Medicina Sperimentale, sapienza university, 00161 - rome/IT
  • 10 Department Of Medical Oncology, Azienda Ospedaliero Universitaria San Luigi Gonzaga, 10043 - orbassano/IT
  • 11 Dipartimento Di Medicina Interna E Specialità Mediche, Università di Genova, 16132 - genova/IT
  • 12 Gastroenterologia Ed Endoscopia Digestiva, Università degli Studi di Milano, 20122 - milano/IT
  • 13 Malattie Dell'apparato Digerente E Fegato, Azienda Ospedaliero-Universitaria Sant'Andrea, 1038 - roma/IT
  • 14 Chirurgia Generale B – Istituto Del Pancreas, Policlinico “G.B. Rossi”, 37134 - verona/IT
  • 15 Dipartimento Di Scienze Mediche E Chirurgiche, università di bologna, 40126 - Bologna/IT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5749


Neuroendocrine neoplasms (NENs) are a group of heterogeneous neoplasms which can be treated with different therapies: in well differentiated (WD) NENs analogs of somatostatin (SSA) can be used considering their proved antineoplastic and antisecretory effects. This is a multicenter study to investigate the safety of high doses (HDD) analogs of somatostatin (SSA) in WD NENs with particular attention for patients over 70 years of age.


We collected clinical data from 13 Italian NENs dedicated Units. Patients with WD NENs, in progression on previous treatments, included SSA, and subsequently treated with HDD-SSA, were considered.


170 pts were included: 61.76% male, 38.24% female. The median age at the diagnosis was 58.83. Regarding the site of origin, the most frequent was gastro-intestinal system (54.71%), followed by pancreas (27.06%) and lung (8.24%). G1 NENs were 54.11%, G2 42.94% and typical lung carcinoid 2.95%; 31.76% were affected by a carcinoid syndrome or clinical conditions such as gastrinoma, insulinoma and Zollinger-Ellison. The median PFS was 20.18 months. Side effects (SEs) were registered in 25 pts (14.71%), the most frequent were cholecystitis (4%), G1 asthenia (12%), G1 hyperglycemia (8%), G1 steatorrhea (76%). We divided patients in 4 groups considering the age at the diagnosis: lower than 60 years, 61-70, 71-80 and more than 81 years. With the increase of age there was a higher percentage of SEs (Tab.1) with a maximum percentage of 20.41% in the group with an age of 71-80 years. The treatment was well tolerated without life-threatening side effects also in the group of patients with an age > 70 years. Tab. 1Table: 520P

Age at the diagnosis (years)% side effects


We concluded that in this setting of patients, with an age >70 and a WD NEN in progression to standard doses of SSA, HD-SSA represents a safe and effective second line therapy with a median PFS of 20.80 months.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.